152 related articles for article (PubMed ID: 35549181)
21. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
22. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.
Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
24. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
[TBL] [Abstract][Full Text] [Related]
26. Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.
Rezende Miranda R; Fu Y; Chen X; Perino J; Cao P; Carpten J; Chen Y; Zhang C
J Med Chem; 2020 Oct; 63(20):11484-11497. PubMed ID: 33030342
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
29. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
[TBL] [Abstract][Full Text] [Related]
30. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
31. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
32. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
33. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
French DM; Lin BC; Wang M; Adams C; Shek T; Hötzel K; Bolon B; Ferrando R; Blackmore C; Schroeder K; Rodriguez LA; Hristopoulos M; Venook R; Ashkenazi A; Desnoyers LR
PLoS One; 2012; 7(5):e36713. PubMed ID: 22615798
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.
Nie W; Lu Y; Pan C; Gao J; Luo M; Du J; Wang J; Luo P; Zhu H; Che J; He Q; Dong X
Bioorg Chem; 2022 Apr; 121():105673. PubMed ID: 35217375
[TBL] [Abstract][Full Text] [Related]
35. Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma.
Shin JY; Ahn SM
J Transl Med; 2021 Apr; 19(1):138. PubMed ID: 33794926
[TBL] [Abstract][Full Text] [Related]
36. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer.
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2023 Nov; 259():115703. PubMed ID: 37556948
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.
Zhang Z; Li J; Chen H; Huang J; Song X; Tu ZC; Zhang Z; Peng L; Zhou Y; Ding K
J Med Chem; 2022 Feb; 65(4):3249-3265. PubMed ID: 35119278
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
40. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
